KNSA

MKT CAP:$4B

Kiniksa Pharmaceuticals Ltd

Market Cap

$4B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$49.04+$7.03 (+16.75%)

Jun 8, 2026

52W High $59.4852W Low $26.33

Company Details

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1be...

CEO

—

IPO Date

May 24, 2018

Website

www.kiniksa.com

Key Metrics TTM

Revenue

$754M

+56.7% YoY

Net Income

$73M

EPS (Diluted)

Free Cash Flow

$164M

Revenue / Share

$9.15

Gross Margin

54.6%

Operating Margin

12.4%

Net Margin

9.7%

FCF Margin

21.8%

P/S

4.9x

P/E

51.0x

Earnings Reports

Q2 2026

Jul 28, 2026

PENDING

Q1 2026

Apr 28, 2026

$214M+55.5%

FY 2025

Feb 24, 2026

$678M+60.1%

Q4 2025

Feb 24, 2026

$202M+65.0%

Q3 2025

Oct 28, 2025

$181M+61.2%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee